Table 4. Seropositivity rates and GMTs/GMCs before (pre-challenge) and 1 month after (post-challenge) a polysaccharide challenge dose had been given (booster ATP cohort for immunogenicity).

		Study vaccine*			Control vaccine**
Antibody	Timepoint to vaccination	N	Seropositivity (%) (95% CI)	GMT or GMC 95% CI)	N	Seropositivity(%) ≥ 1: 8 (95% CI)	GMT or GMC (95% CI)
SBA-MenA	Pre-challenge	109	47.7 (38.1, 57.5)	27.8 (18.2, 42.3)	103	25.2 (17.2, 34.8)	12.2 (8.3, 18.1)
	Post-challenge	107	93.5 (87.0, 97.3)	390.1 (280.2, 543.0)	109	51.4 (41.6, 61.1)	46.4 (28.8, 74.7)
SBA-MenC	Pre-challenge	117	56.4 (46.9, 65.6)	31.6 (21.9,45.8)	116	5.2 (1.9, 10.9)	4.6 (4.0, 5.1)
	Post-challenge	122	88.5 (81.5, 93.6)	593.5 (398.1, 884.7)	121	18.2 (11.8, 26.2)	8.7 (6.2, 12.3)
Anti-PSA	Pre-challenge	115	23.5 (16.1, 32.3)	0.21 (0.19, 0.24)	115	5.2 (1.9, 11.0)	0.16 (0.15, 0.17)
	Post-challenge	120	90.8 (84.2, 95.3)	4.72 (3.41, 6.52)	117	47.0 (37.7, 56.5)	0.38 (0.30, 0;48)
Anti-PSC	Pre-challenge	116	78.4 (69.9, 85.5)	0.62 (0.52, 0.73)	113	4.4 (1.5, 10.0)	0.17, (0.15, 0.18)
	Post-challenge	119	98.3 (94.1, 99.8)	4.29 (3.57, 5.14)	121	100 (97.0, 100)	3.58 (3.03, 4.24)

^*DTPw-HBV/Hib-MenAC

^**DTPw-HBV/Hib

PSA/C = serogroup A/C polysaccharide ; % subjects = percentage of subjects with seroprotective/seropositive titre/concentration of at least 1:8 (SBA-MenA/C), 0.3 μg/ml (anti PSA/C), 95% CI = 95% confidence interval

GMT/GMC = geometric mean antibody titre/concentration calculated on all subjects.